{"contentid": 487917, "importid": NaN, "name": "Merck & Co follows AstraZeneca in voluntarily withdrawing indication", "introduction": "US pharma giant Merck & Co became the second company in as many weeks to voluntarily withdraw a US indication for one of its drugs.", "content": "<p>US pharma giant Merck &amp; Co (NYSE: MRK) became the second company in as many weeks to voluntarily withdraw a US indication for one of its drugs.</p>\n<p>Merck will cease to market Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.</p>\n<p>This decision does not affect other indications for Keytruda, Merck&rsquo;s immuno-oncology blockbuster.</p>\n<p><span class=\"pullQuote\">\"The accelerated pathways created by the FDA have been integral to the remarkable progress in oncology\"</span>The US Food and Drug Administration (FDA) granted accelerated approval for Keytruda in this indication in June 2019 based on tumor response rate and durability of response data from KEYNOTE-158 and KEYNOTE-028.</p>\n<p>Continued approval for this indication was contingent upon completion of the post-marketing requirement establishing superiority of Keytruda as determined by overall survival (OS).</p>\n<p>As announced in January 2020, KEYNOTE-604, the confirmatory Phase III trial for this indication, met one of its dual primary endpoints of progression-free survival but did not reach statistical significance for the other primary endpoint of OS.</p>\n<p>Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said: &ldquo;The accelerated pathways created by the FDA have been integral to the remarkable progress in oncology care over the past five years and have helped many cancer patients with advanced disease, including SCLC, access new treatments.</p>\n<p>&ldquo;Keytruda remains a foundational treatment for certain patients with metastatic non-small cell lung cancer. We will continue to rigorously evaluate the benefits of Keytruda in SCLC and other types of cancer, in pursuit of Merck&rsquo;s mission to save and improve lives.&rdquo;</p>\n<p>Only last week, AstraZeneca (LSE: AZN) <a href=\"https://www.thepharmaletter.com/article/imfinzi-trial-failure-prompts-withdrawal-of-indication-in-usa\" rel=\"follow\">announced</a> the voluntary withdrawal of the Imfinzi (durvalumab) indication in the USA for previously-treated adults with locally advanced or metastatic bladder cancer. Again, continued approval was contingent upon trial results, which ultimately disappointed.</p>", "date": "2021-03-02 12:26:00", "meta_title": NaN, "meta_keywords": "indication, Merck, Keytruda, voluntarily, cancer, accelerated, withdrawing, giant, AstraZeneca, pharma, drugs, withdraw, weeks, company, patients, KEYNOTE-", "meta_description": "US pharma giant Merck & Co became the second company in as many weeks to voluntarily withdraw a US indication for one of its drugs.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-02 12:08:05", "updated": "2021-03-02 13:36:01", "access": NaN, "url": "https://www.thepharmaletter.com/article/merck-co-follows-astrazeneca-in-voluntarily-withdrawing-indication", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merck_co_large.png", "image2id": "merck_co_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Drug Trial, Focus On, Management, Regulation, Research", "geography_tag": "USA", "company_tag": "AstraZeneca, Merck & Co", "drug_tag": "Keytruda", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-02 12:26:00"}